NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
Astellas Pharma Inc
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
University of California, San Diego
Nanjing Leads Biolabs Co.,Ltd
Hoffmann-La Roche
National Cancer Institute, Naples
Theriva Biologics SL